更新于：2024-11-01

Crotaline Snake Venom

Crotaline 蛇毒

更新于：2024-11-01

基本信息

别名

Crotaline Snake Venom、Snake Venom, Crotaline、Venom, Crotaline Snake

简介-

关联

项与 Crotaline 蛇毒相关的药物

VIPERFAV

靶点-

作用机制

免疫刺激剂

在研机构

MicroPharm Ltd.

原研机构

MicroPharm Ltd.

在研适应症

Crotaline 蛇毒

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

法国

首次获批日期2023-03-21

BOTHROFAV

靶点-

作用机制

免疫刺激剂

在研机构

MicroPharm Ltd.

原研机构

MicroPharm Ltd.

在研适应症

Crotaline 蛇毒

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

法国

首次获批日期2020-10-30

EchiTAbG

靶点-

作用机制-

在研机构

MicroPharm Ltd.

原研机构

MicroPharm Ltd.

在研适应症

Crotaline 蛇毒

非在研适应症-

最高研发阶段批准上市

首次获批国家/地区

英国

首次获批日期2019-06-20

项与 Crotaline 蛇毒相关的临床试验

NCT04470791 / CompletedN/AIIT

Cryotherapy as a Coadjuvant in the Management of Crotaline Snakebite With F(ab')2 Antivenom: A Randomized Pilot Study.

The study aimed to determine the effect of local cryotherapy as a coadjuvant in patients with snakebite treated with F(ab')2 therapy venom at the Hospital Juárez de Mexico.

开始日期2015-01-01

申办/合作机构-

NCT00927381 / CompletedN/A

Retrospective Evaluation of Treatments and Outcomes Associated With Antivenom Therapy For Crotaline Snakebite - A Comparison Of Severe To Mild/Moderate Envenomations

Retrospective observational review of severe envenomation treatment with CroFab

开始日期2005-01-01

申办/合作机构

BTG International, Inc.

100 项与 Crotaline 蛇毒相关的临床结果

登录后查看更多信息

100 项与 Crotaline 蛇毒相关的转化医学

登录后查看更多信息

0 项与 Crotaline 蛇毒相关的专利（医药）

登录后查看更多信息

项与 Crotaline 蛇毒相关的文献（医药）

2022-09-14·The American Journal of Tropical Medicine and Hygiene

Case Report: Management of an Uncommon Crotaline Snakebite (Ovophis makazayazaya)

作者: Huang, Chia-Chun ; Mao, Yan-Chiao ; Lai, Chih-Sheng ; Luo, Yi ; Chiang, Liao-Chun ; Liu, Po-Yu ; Lin, Wen-Loung

ABSTRACT.Ovophis makazayazaya bite is an uncommon cause of snakebite that humans may sustain as a result of the continuous overexploitation of forest habitats and excessive development in Taiwan. Although the Taiwanese government has produced four antivenoms against medically important snakebite accidents, O. makazayazaya is not among the snakes for which an antivenom has been produced. A case of O. makazayazaya snakebite on a patient’s right foot, which later swelled into the hip, is reported. In vitro studies have reported that monovalent antivenoms for Gloydius brevicaudus and Trimeresurus albolabris, and polyvalent antivenom for Calloselasma rhodostoma, Daboia siamensis, and T. albolabris show reactivity toward Ovophis venoms. However, these antivenoms are unavailable in Taiwan. Thus, bivalent antivenom for Trimeresurus stejnegeri stejnegeri and Protobothrops mucrosquamatus was used, assuming similar immunoreactivity and a possible para-specific effect of green pit viper antivenom against this Ovophis venom. A favorable outcome was observed, without significant extension in prothrombin time and activated partial thromboplastin time. In addition, no systemic bleeding occurred. Nonetheless, further venom and antivenom evaluations should ascertain the efficacy of this para-specific antivenoms against this crotaline snakebite.

2022-05-04·Clinical Toxicology3区 · 医学

Predictors of FabAV use in copperhead envenomation

3区 · 医学

Article

作者: Condren, Michelle ; Woslager, Megan ; Hendrix, Amy ; Rainey Kiehl, Robin ; Baab, Kelsey ; Larsen, Adam ; Ramirez-Cueva, Fatima ; Knowlton, Elise

CONTEXTCrotaline snake envenomation is a serious medical condition affecting thousands of Americans each year. Variation in the treatment of Crotaline snakebites exists among physicians in the United States. Management of copperhead snakebites is controversial with some experts advocating minimal intervention, rarely necessitating antivenom use and, even more rarely, surgical intervention. This study assessed the use of Crotaline Polyvalent Immune Fab antivenom (Ovine) (FabAV) and explored factors influencing the decision to prescribe antivenom for copperhead envenomation in patients in Northeastern Oklahoma.METHODSA retrospective cohort study examining electronic medical records of patients with copperhead snakebites from July 1, 2014 to August 31, 2019. Data collected included: patient demographics, transfer information, snake species, bite site, progression of local tissue effects, additional clinical and lab results, patient comorbidities, and treatment strategy. Associations between patient variables and treatment were evaluated using the chi-square test of independence, median test, and logistic regression analysis. Associations were statistically significant if p < 0.05.DISCUSSIONOf the 130 patients bitten by a copperhead, a majority (75%) received FabAV. Symptoms of copperhead envenomation were mostly limited to the progression of tissue damage. Predictors of treatment with FabAV included progression of venom effects across major joints, younger age, comorbidities, and upper extremity bites.CONCLUSIONSPatients who have multiple comorbidities, upper extremity bites and progression of venom effects across major joints are more likely to be treated with FabAV. The high usage of FabAV at the study site underscores the need for continued work to optimize the use of antivenom for copperhead envenomations.

2017-02-07·Clinical Toxicology3区 · 医学

Coagulation parameters in copperhead compared to otherCrotalinaeenvenomation: secondary analysis of the F(ab’)₂versus Fab antivenom trial

3区 · 医学

Article

作者: Brown, Michael W. J. ; Vissoci, Joao R. Nickenig ; Gerardo, Charles J. ; Bush, Sean P.

CONTEXTCoagulation derangements in copperhead envenomation are considered less severe than other crotaline envenomations, resulting in recommendations to limit both coagulation testing and antivenom treatment. A prospective, blinded, multicenter, randomized clinical trial comparing the effectiveness of F(ab')₂ versus Fab antivenom in crotaline envenomation patients was completed in 2011. We determined the difference between coagulation parameters in copperhead compared to other crotaline envenomations.METHODSWe performed a post hoc analysis comparing the coagulation parameters (platelets and fibrinogen) prospectively obtained in the aforementioned trial. All the patients received antivenom in one of three treatment arms [F(ab')₂ with maintenance, F(ab')₂ with placebo maintenance, or Fab with maintenance]. Coagulation parameters were measured at pretreatment baseline, during acute hospitalization, day 5, day 8, and day 15 post-envenomation. Mean platelet count and fibrinogen levels for the copperhead and other crotaline groups were compared. The platelet and fibrinogen point estimates with distribution are presented graphically over time.RESULTS122 patients were enrolled in the study. There were 22 patients with copperhead envenomation, 93 with other crotaline envenomations, and 7 that could not be definitively determined. The mean age was 42 (SD 20) years. There was a minor pretreatment difference in mean baseline platelet count between the copperhead group (246 × 109/L 95% CI 215, 277) compared to other crotaline envenomation patients (184 × 109/L 95% CI 167, 202). There was a modest pretreatment difference in mean fibrinogen level between copperhead patients (345 mg/dL 95% CI 277, 415) and other crotaline patients (261mg/dL 95% CI 241, 281). Pretreatment coagulation parameter means were normal and converged post treatment.CONCLUSIONOn average, copperhead envenomations have less severe initial coagulation derangements. However, in mild envenomations, differences in laboratory values are minimal and there is substantial variation in individual patients regardless of species. Species alone should not be used to determine the need for laboratory testing or treatment in crotaline snakebite.